RxDoctor Payments DataLook up a doctor →

George Monks, MD

Dermatology · Tulsa, OKNPI 1891781779

Payments from drug & device makers

$530,392in general payments, 2019–2025

Across 1,427 payments — averaging $371.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$210K
  • Sun Pharmaceutical Industries Inc.$131K
  • Amgen$111K
  • Novartis$15K
  • Bristol Myers Squibb$13K
  • Genentech USA, Inc.$13K
  • plus $38K from 28 others

What the payments were for

  • Consulting fees$77,33815%
  • Speaking & faculty fees$380,57072%
  • Travel & lodging$46,5889%
  • Food & beverage$25,4575%
  • Education$4390%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$530,392 in reported general payments places this provider in the 95th percentile of 114 dermatology providers in Oklahoma.

See all dermatology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$448,643
Medicare patients
1,492
Services billed
6,698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OdomzoSonidegib Phosphate43$581,471
Cosentyx Sensoready (2 Pens)Secukinumab51$373,538
Skyrizi PenRisankizumab-Rzaa11$227,618
Humira(Cf) PenAdalimumab19$141,870
OtezlaApremilast28$132,300
Cosentyx Unoready PenSecukinumab11$102,597
Dupixent PenDupilumab20$81,497
ZoryveRoflumilast13$17,866
Imiquimod339$12,949
Triamcinolone Acetonide716$8,582
Ketoconazole254$4,191
Metronidazole93$3,294
Betamethasone Dipropionate51$2,736
Clobetasol Propionate52$2,702
ValacyclovirValacyclovir Hcl64$2,588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$111,254$132,30028 claims
Arcutis Biotherapeutics, Inc.Zoryve$579$17,86613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 114 dermatology providers in Oklahoma.

Other dermatology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →